Sars Cov 2 - Pharma

Relevant Publications

Characterization of proinflammatory cytokines profile during acute SARS-CoV-2 infection in people with human immunodeficiency virus.

Issue Release: 2024

14-3-3 Family of Proteins: Biological Implications, Molecular Interactions, and Potential Intervention in Cancer, Virus and Neurodegeneration Disorders.

Issue Release: 2024

Finding Long-COVID: Temporal Topic Modeling of Electronic Health Records from the N3C and RECOVER Programs.

Issue Release: 2024

Seroprevalence of SARS-CoV-2 and risk factors for infection among children in Uganda: a serial cross-sectional study.

Issue Release: 2024

Information theory reveals physiological manifestations of COVID-19 that correlate with symptom density of illness.

Issue Release: 2024

The timing of local SARS-Cov-2 outbreaks and vaccination coverage during the Delta wave in Melbourne.

Issue Release: 2024

[Pharmacological characteristics and clinical study results of ensitrelvir fumaric acid (XOCOVA Tablets 125 ‍mg)].

Issue Release: 2024

Harnessing host enhancers of SARS-CoV-2 entry as novel targets for antiviral therapy.

Issue Release: 2024

A 67-Year-Old Man with Chronic Lymphocytic Leukemia (CLL) on Maintenance Therapy with Ibrutinib with Persistent SARS-CoV-2 Infection Unresponsive to Antiviral Treatments.

Issue Release: 2024

Nucleated red blood cells as a prognostic marker for mortality in patients with SARS-CoV-2-induced ARDS: an observational study.

Issue Release: 2024

Demographic Characteristics, Clinical Profile, Outcome and Risk Factors of Covid-19 among Health Care Workers in a COVID Dedicated Hospital.

Issue Release: 2024

Imprinting of IgA responses in previously infected individuals receiving bivalent mRNA vaccines (WT and BA.4/BA.5 or WT and BA.1).

Issue Release: 2024

Genomic surveillance of SARS-CoV-2 and emergence of XBB.1.16 variant in Rajasthan.

Issue Release: 2024

Real-World Effectiveness of Nirmatrelvir in Protecting Long COVID for Outpatient Adult Patients - A Large-Scale Observational Cohort Study from the RECOVER Initiative.

Issue Release: 2024

Rapid Development of a Registry to Accelerate COVID-19 Vaccine Clinical Trials.

Issue Release: 2024

Miscarriage after SARS-CoV-2 vaccination: A request to report more details of the regression models and analyses.

Issue Release: 2024

SARS-CoV-2 BA.4/5 infection triggers more cross-reactive FcγRIIIa signaling and neutralization than BA.1, in the context of hybrid immunity.

Issue Release: 2024

Comprehensive proteomic analysis of HCoV-OC43 virions and virus-modulated extracellular vesicles.

Issue Release: 2024

Reduced IFNL1 and/or IFNL2, but not IFNL3 is associated with worse outcome in patients with COVID-19.

Issue Release: 2024

Structure-Guided Design of Potent Coronavirus Inhibitors with a 2-Pyrrolidone Scaffold: Biochemical, Crystallographic, and Virological Studies.

Issue Release: 2024

What Role Does Cellular Stress Play in Disease?

What are the Implications for Pharma Companies?

Why do Pharma Companies Use CROs?

What is Patient Education in Pharma?

What Should Be Included in Patient Education Materials?

How Can ADEs be Prevented?

Why is Regulatory Approval Important?

How Can Pharmacists Contribute to Transitional Care?

What is the Future of ADE Management?

How Does Cellular Stress Impact Drug Development?

Partnered Content Networks

Relevant Topics